Tumor necrosis factor-␣ converting enzyme (TACE) is a membrane-anchored, Zn-dependent metalloprotease, which belongs to the ADAM (a disintegrin and metalloprotease) family. TACE functions as a membrane sheddase to release the ectodomain portions of many transmembrane proteins, including the precursors of TNF␣, TGF␣, several other cytokines, as well as the receptors for TNF␣, and neuregulin (ErbB4). Mice with TACE ⌬Zn/⌬Zn null mutation die at birth with phenotypic changes, including failure of eyelid fusion, hair and skin defects, and abnormalities of lung development. Abnormal fetal heart development was not previously described. Herein, we report that TACE ⌬Zn/⌬Zn null mutant mice by late gestation exhibit markedly enlarged fetal hearts with increased myocardial trabeculation and reduced cell compaction, mimicking the pathological changes of noncompaction of ventricular myocardium. In addition, larger cardiomyocyte cell size and increased cell proliferation were observed in ventricles of TACE ⌬Zn/⌬Zn knockout mouse hearts. At the molecular level, reduced expression of epidermal growth factor receptor, attenuated protein cleavage of ErbB4, and changes in MAPK activation were also detected in TACE ⌬Zn/⌬Zn knockout heart tissues. The data suggest that TACE-mediated cell surface protein ectodomain shedding plays an essential and a novel regulatory role during cardiac development and modeling.
Introduction
A wide variety of cell surface transmembrane proteins, including cytokines, growth factors, receptors, and adhesion molecules, can be released from the cell surface by a proteolytic process, which is referred to as "ectodomain shedding" (Kheradmand and Werb, 2002) . Since many cytokines and growth factors are initially synthesized as transmembrane precursors with low biological activity or limited accessibility, specific cleavage of these precursor proteins to release their active soluble forms is one of the key regulatory steps to change their biological activities. On the other hand, cleavage of the extracellular portions of the transmembrane receptors can downregulate these receptor functions by abrogating the ligand binding activity. Therefore, protein ectodomain shedding may regulate cell prolif-eration, differentiation, and survival through changing the interaction of cells with their surrounding environment in multiple ways. Tumor necrosis factor-␣ converting enzyme (TACE, or ADAM17) is one of the well-characterized cell membrane sheddases (Black, 2002) , and belongs to the family of a disintegrin and metalloprotease (ADAM) (Primakoff and Myles, 2000) . TACE has Zn-dependent metalloprotease activity that cleaves the transmembrane form of tumor necrosis factor-␣ (TNF-␣) and releases an active and soluble form of TNF-␣ (Moss et al., 1997; Black et al., 1997) . However, specific protein ectodomain shedding by TACE is not restricted to TNF-␣. Many cell membranebound proteins, including TGF-␣, L-selectin, amyloid-␤ precursor protein, Notch-1 receptor, TRANCE, ErbB4, TNF␣ receptors (p75 and p55), as well as Type II IL-1 receptor, have been reported to be cleaved by TACE in certain cell types under certain conditions (Sunnarborg et al., 2002; Peschon et al., 1998; Lum et al., 1999; Brou et al., 2000; Rio et al., 2000; Buxbaum et al., 1998) .
Abrogation of TACE's function in mice by genetically deleting zinc-binding domain (TACE ⌬Zn/⌬Zn ) resulted in perinatal lethality with several observable phenotypes, including failure of eyelid fusion, hair and skin defects, and abnormal lung development Zhao et al., 2001) . This set of characteristics does not occur in TNF-␣-deficient mice (Marino et al., 1997; Pasparakis et al., 1996) . However, some phenotypes do closely resemble the phenotypic features of TGF-␣ knockout mice (Luetteke et al., 1993) . Subsequent studies showed that cells from TACE ⌬Zn/⌬Zn mice release little TGF-␣ (Sunnarborg et al., 2002; Peschon et al., 1998) . However, TGF-␣ null mutant mice do not die prematurely, suggesting that TACE has additional substrates required for development of some important organs that are essential for survival. One of such organ may be the heart. The abnormal myocardial development phenotype reported herein has not been described in the previous studies.
The heart is the first organ to form during embryonic development in vertebrates. It arises through a complex series of morphogenetic interactions involving cells from several embryonic origins (Olson and Srivastava, 1996; MacLellan and Schneider, 2000) . The early heart developmental process includes formation of the primitive cardiac tube, looping of the cardiac tube to the right, and chamber specification and formation. Then, during maturation of the fetal heart, cardiomyocytes exhibit two related but distinct modes of growth that are highly regulated. The ventricular mass of the fetal heart is augmented by cardiomyocyte proliferation, also termed hyperplasia, which decreases progressively in late gestation and ceases soon after birth. Increases in cardiac mass postnatally are achieved preponderantly through increased cell volume, termed hypertrophy, and not by cell proliferation, since the cardiomyocytes have permanently exited the cell cycle. These complicated cardiac morphogenetic events must be coordinated by many fine-tuned, as yet unidentified factors. Changes in these homeostatic factors, such as TACE, may contribute to developmental anomalies of the heart.
Mutation of a wide variety of genes in mice results in abnormal development of the myocardial wall. For example, mice homozygous for a null mutation in the gene encoding retinoid X receptor-␣ display ventricular chamber hypoplasia and muscular ventricular septal defects (Sucov et al., 1994) . A similar phenotype is also seen in mice carrying mutation in N-myc, TEF1, NF1, and ␤-ARK1 genes (Brannan et al., 1994; Chen et al., 1994; Charron et al., 1992; Jaber et al., 1996) . In contrast, null mutations in several other genes, such as heparin-binding epidermal growth factor (HB-EGF), ErbB2, HOP, PTEN, and phospholamban, result in myocardial hyperplasia, and/or hypertrophy as well as reduced contractile function (Iwamoto et al., 2003; Ozcelik et al., 2002; Crone et al., 2002; Shin et al., 2002; Crackower et al., 2002; Schmitt et al., 2003) . Null mutation of FKBP12 results in a defect in the compact layer of ventricular myocardium with an increased trabecular layer, resembling the human disorder, "noncompaction of the ventricular myocardium" (Shou et al., 1998; Chin et al., 1990) . The diversity of genes affecting myocardial growth suggests that cardiac development is particularly sensitive to perturbations. Although many cardiac malformations are well characterized anatomically and physiologically, there is still little understanding of the genetic basis of these abnormalities. Herein, we show that null mutation of the TACE gene induces abnormal myocardial development in TACE ⌬Zn/⌬Zn knockout mice, and altered cellular signal transduction. This is the first time that a congenital fetal myocardial growth phenotype due to abrogation of endogenous TACE activity has been characterized.
Materials and methods
Mice TACE ⌬Zn/⌬Zn mutant mice (C57BL/6) with inactivated TACE activity were kindly provided by Dr. Jacques Peschon at Amgen (Seattle, WA) . Homozygous TACE ⌬Zn/⌬Zn null mutant (Ϫ/Ϫ) mice were produced by cross-breeding TACE heterozygous (ϩ/Ϫ) mice overnight. The presence of a vaginal plug was counted as gestation day 0.5 (E0.5). Fetal hearts were isolated under a dissecting microscope from E15.5 to newborn (P1) mice, and TACE genotypes were verified by genomic DNA PCR analysis as documented previously (Zhao et al., 2001) .
Heart histology
Fetal mice at different gestational ages were fixed in 4% paraformaldehyde and embedded in paraffin. Transverse sections across the middle part of the heart were obtained at 6 m thickness and mounted onto HistoGrip-coated microscopic slides (Zymed, San Francisco, CA). Hematoxylin and eosin (H&E) staining was used to analyze the heart morphological differences between wild-type and TACE ⌬Zn/⌬Zn null mutant mice.
Total RNA isolation and quantitative RT-PCR
The total RNA was isolated from heart tissues by using a Qiagen RNeasy kit (Qiagen Inc., Santa Clarita, CA). Total RNA (2 g) was added to a 20-l reverse transcription reaction mixture with 200U SUPERSCRIPT II (Invitrogen, Carlsbad, CA) and incubated at 42°C for 60 min. The RT reaction product was further diluted and applied to PCR analysis. The competitive RT-PCR method for quantification of TACE gene expression has been described previously (Shi et al., 1999) .
Real-time quantitative RT-PCR analysis was performed on iCycler-iQ system (Bio-Rad Laboratories, Hercules, CA) by using SYBR Green I dye detection. The reactions were assembled following manufacturer's recommendation.
Briefly, 25 l of reaction mixture contains 1 ϫ iQ SYBR Green Supermix (Bio-Rad), 200 nM forward and reverse primers, and the cDNA template from the RT reaction sample. The PCR conditions are 3 min at 95°C followed by 40 cycles of 10 s at 95°C, 30 s at annealing temperature, and 30 s at 72°C. The specificity of PCR was verified by measuring the melting curve of the PCR product in the end of reaction. Fluorescent data are specified for collection during the 72°C step. The relative cDNA ratio was calculated by using ⌬⌬CP [CP, Crossing point that is equivalent to threshold cycles (Ct); Pfaffl, 2001] . The PCR primer sequences are: ANF (GGTCTTGCCTCTCCACTCT and CA-GAAGCCAAAGAAGCACATCA); BNP (GAGTCCT-TCGGTCTCAAGGCAG and GCCCAAACGACTGACG-GATC); MyHC-␣ (GACATTGGTGCCAAGAAG and CGAACGTTTATGTTTATTGTG); MyHC-␤ (CAAG-GGCCTGAATGAGGAG and CCACCTAAAGGGCTGT-TGC); skeletal ␣-actin (AATGCTTCTAGGCGCACTCG and GTACACGTCAAAAACAGGCGC); cardiac ␣-actin (CTCTCTGTCCACCTTCCAG and TACAATGACTGAT-GAGAGATGG). GAPDH was used as reference control to normalize equal loading of template cDNA.
Immunohistochemistry
Tissue sections were deparaffinized, rehydrated, and processed for immunohistochemical studies by using Zymed Histostain-Plus system (Zymed). TACE antibody was purchased from Santa Cruz Biotech (Santa Cruz, CA). Nonimmune serum was used as negative control, and lung section staining was used as a positive control as reported previously (Zhao et al., 2001) .
BrdU labeling and cell proliferation in vivo
BrdU labeling during DNA synthesis in mitotic cells was used to measure cell proliferation rate. Briefly, BrdU (0.1 mg/g body weight) was intraperitoneally injected into the pups 3 h before heart isolation. The paraformaldehyde-fixed and paraffin-embedded heart tissue sections were then immunostained by using a BrdU immunostaining kit (Zymed) to detect proliferating cells with nuclear incorporated BrdU. DAB was used as the chromogenic substrate in final color development. The percentages of positively stained cells were counted in five randomly selected fields by microscopy at high magnification.
Cell apoptosis
The apoptotic cells in heart tissue sections were detected by using ApopTag kit (Intergen, Purchase, NY). Briefly, the deparaffinized tissue sections were treated with 20 g/ml proteinase K for 15 min. The endogenous peroxidase was then quenched in 3% H 2 O 2 in PBS for 5 min. The free 3Ј-OH ends of DNA fragments in apoptotic cells were labeled with digoxigenin (DIG)-dNTP by terminal deoxynucleotidyl transferase for 1 h at 37°C. The labeled DIG was then detected by immunostaining with anti-DIG antibody-conjugated HRP. DAB was used as a chromogenic substrate, and the slides were counterstained with 0.5% methyl green.
Western blot
Detection of a specific protein has been previously described (Zhao et al., 2000) . Briefly, heart tissues were homogenized on ice in RIPA buffer: 1% Nonidet P-40, 0.25% sodium deoxycholate, 0.1% SDS, 50 mM sodium floride, 5 mM EDTA, and freshly added 1 mM PMSF, 0.2 U/ml, aprotinin, and 1 mM sodium orthovanadate. Protein concentration was estimated by the Bradford method (Bio-Rad). Total tissue lysate proteins (30 g) were loaded in each lane for SDS-PAGE, and the separated proteins were transferred to Immobilon-P membrane (Millipore, Bedford, MA). The membrane was then blocked for nonspecific binding overnight at 4°C by incubating membrane in either 5% fat-free drymilk in TBST (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% Tween 20) for specific protein detection, or 3% bovine serum albumin in TBST for protein phosphorylation detection. Primary antibody was diluted in blocking buffer and incubated with the membrane for 1 h at room temperature. After washing the membrane in TBST (10 min ϫ 4), HRP-conjugated secondary antibody was added for 45 min at room temperature. The antibody detected protein bands were visualized by ECL reagent (Amersham, Piscataway, NJ), and recorded on Kodak BioMax film. Antibodies for EGFR, ErbB4, ERK, JNK, pJNK, and p38 were purchased from Santa Cruz, and antibodies for pERK and pp38 were from Cell Signaling Technology (Beverly, MA).
Results

TACE expression in mouse fetal heart
In order to evaluate the role of TACE during fetal heart development, expression of TACE mRNA in mouse fetal heart during different developmental stages was determined by competitive RT-PCR ( Fig. 1A and B ). Expression of TACE at mRNA level was the highest at early embryonic stage (E11.5) and was reduced during mid-late gestation (E14.5 to P1). Interestingly, there was a slight increase of TACE mRNA expression at late embryonic stage (E18.5). Cellular localization of TACE protein in fetal heart was analyzed by immunohistochemistry ( Fig. 1C and D) . TACE protein was detected in a dispersed pattern in both atrium and ventricle at E16.5. However, the intensity of staining was stronger on the endocardial side of the myocardial wall compared with the compact layer of myocardium on the epicardial side, and particularly among the trabecular structures.
TACE ⌬Zn/⌬Zn null mutant mice exhibit enlarged heart by late gestation stage A significantly enlarged fetal heart size, including both atria and ventricles, was observed in TACE ⌬Zn/⌬Zn knockout mice after E18.5 compared with wild-type mice. The abnormal enlargement of heart size in TACE ⌬Zn/⌬Zn mice reached a maximum on postnatal day 1 ( Fig. 2A) , when most TACE ⌬Zn/⌬Zn knockout mice died. Histologically the atrial and ventricular chambers and the thickness of ventricular myocardium at E15.5 were similar between wildtype and TACE ⌬Zn/⌬Zn knockout mice (Fig. 2B ). However, both atrial and ventricular chambers in TACE ⌬Zn/⌬Zn mice by late gestation (E18.5) and neonates (P1) were larger than in wild-type mice. The ventricular wall at E18.5, particularly the trabecular layer, was thicker in TACE ⌬Zn/⌬Zn mice than in wild-type mice, and ventricular trabeculae had deep recesses ( Fig. 2B) . At P1 stage, the cardiomyocytes in TACE ⌬Zn/⌬Zn knockout hearts were more loosely packed with larger extracellular spaces ( Fig. 2C ), though excessive collagen deposits were not detected by trichrome staining (data not shown). The diameter of the cardiomyocytes in P1 TACE ⌬Zn/⌬Zn heart was clearly increased as viewed under high magnification (Fig. 2C) . No valve and chamber septation defect were observed. Furthermore, the fetal heart enlargement in E18.5 TACE ⌬Zn/⌬Zn mice was quantitatively evaluated by comparison of the isolated heart weight between wild-type and TACE ⌬Zn/⌬Zn knockout mice (Table Fig. 1 . Temporo-spatial expression pattern of TACE in mouse fetal heart. (A, B) TACE expression at mRNA level during heart development was measured by competitive RT-PCR. PCR products were analyzed on agarose gel (A), and the band intensities were quantified to determine the relative levels of TACE mRNA expression (B). ␤-Actin was used as a control. Significant difference (*, P Ͻ 0.05) was detected for the difference of TACE mRNA levels between E16.5 and E18.5. (C, D) TACE protein cellular localization at E16.5 was detected by immunostaining. TACE was dispersed throughout the whole heart, but the staining in ventricular sepatum and trabeculae was more intense (C). The boxed area in (C) was further viewed under high magnification (D). Scale bar: 200 m. *, Specific staining in lung peripheral epithelial cells is noted as a positive control (Zhao et al., 2001) . 1). Since most TACE ⌬Zn/⌬Zn fetuses had smaller body size compared with their littermates, the isolated heart weight was normalized as the heart weight-to-body weight ratio. In TACE ⌬Zn/⌬Zn null mutant mice (Ϫ/Ϫ), there was about a 20ϳ30% increase (P Ͻ 0.05) in the heart weight-to-body weight ratio number compared with the numbers in wildtype (ϩ/ϩ) and heterozygous (ϩ/Ϫ) mice, which have a normal cardiac phenotype. The diameter of cardiomyocytes in P1 TACE ⌬Zn/⌬Zn knockout heart was larger than in wild-type, and the TACE ⌬Zn/⌬Zn knockout cells were more loosely packed together. Scale bar: 20 m. Fig. 3 . Comparison of cell proliferation and apoptosis between P1 TACE ⌬Zn/⌬Zn knockout mouse heart (KO) and its wild-type control (WT). (A, B) Cell proliferation in neonatal mouse hearts (P1) was measured by BrdU labeling. There were more BrdU-positive cells (brown color) in the ventricular tissue section stained by anti-BrdU antibody (A, scale bar: 25 m), and the cell proliferation index in TACE ⌬Zn/⌬Zn knockout mouse heart was quantified as 14 Ϯ 3% versus 8 Ϯ 1% in wild-type control (B; *, P Ͻ 0.05). (C) Detection of apoptotic cells by TUNEL assay. Only a few apoptotic cells were detected in both TACE ⌬Zn/⌬Zn knockout and wild-type control sections, as pointed by black arrows. Scale bar: 25 m.
Increased cell proliferation in newborn of TACE ⌬Zn/⌬Zn knockout mouse hearts
The heart enlargement seen in the TACE ⌬Zn/⌬Zn knockout mice could result from increased cell volume (hypertrophy) and/or increased cell number, which is controlled by the rates of cell proliferation and cell apoptosis. Therefore, cardiac cell proliferation and cell apoptosis were measured, although the enlarged cardiomyocytes observed in the TACE ⌬Zn/⌬Zn heart could possibly account for the increased heart size. The index of proliferating cells in the P1 heart, as shown by BrdU labeling, was significantly higher in the TACE ⌬Zn/⌬Zn knockout mice than in wild-type littermate controls ( Fig. 3A and B ), although no differences were observed at earlier developmental stages (E16.5, data not shown). However, cell apoptosis was similar in the P1 TACE ⌬Zn/⌬Zn hearts compared with wild-type controls (Fig. 3C) .
Changes of cardiac specific gene expression in TACE ⌬Zn/⌬Zn knockout heart
In order to further characterize TACE ⌬Zn/⌬Zn knockout heart, changes of several cardiac-specific gene expression were evaluated by real-time PCR (Fig. 4) . These genes included atrial natriuretic factor (ANF), B-type natriuretic peptide (BNP), ␣and ␤-myosin heavy chain (␣-MyHC and ␤-MyHC), skeletal ␣-actin, and cardiac ␣-actin. Alteration of this gene expression is usually associated with abnormal cardiac structure and contractile function, such as myocardial hypertrophy. In the TACE ⌬Zn/⌬Zn null mutant mouse heart at P1 stage, expression of ANF, skeletal ␣-actin, cardiac ␣-actin, and ␣-MyHC was significantly increased, especially skeletal ␣-actin, where a sixfold increase was detected. However, no changes of BNP and ␤-MyHC expression were observed.
Altered EGFR family proteins in TACE ⌬Zn/⌬Zn knockout heart
Many of the epidermal growth factor receptor (EGFR) family proteins, including EGFR, ErbB2, and ErbB4, play important regulatory roles during myocardial development and modeling. Ectodomain shedding of heparin-binding EGF (HB-EGF), one of the EGFR ligands, is required for transactivation of EGFR during G-protein-coupled receptor (GPCR)-activated cardiac hypertrophy (Prenzel et al., 1999) , while ErbB4 is essential for normal myocardial trabeculation (Gassmann et al., 1995; Meyer and Birchmeier, 1995) . Since TACE has been shown to regulate the ectodomain shedding of ErbB4 and possibly HB-EGF in vitro (Rio et al., 2000; Merlos-Suarez et al., 2001) , we therefore examined EGFR and ErbB4 proteins in TACE ⌬Zn/⌬Zn knockout heart. We found that expression of EGFR in TACE ⌬Zn/⌬Zn knockout mouse heart at P1 stage is dramatically decreased compared with wild type control (Fig. 5) , and the related phosphorylation of EGFR was also reduced (data not shown). Moreover, cleavage of ErbB4 was reduced, but not abrogated in TACE ⌬Zn/⌬Zn null mutant heart tissue at P1 stage, as shown by increased full-length ErbB4 (180 kDa, Fig. 5 ) and reduced cleaved product (80 kDa, Fig.  5 ) compared with wild-type control. If ectodomain shedding of receptor ErbB4 is a negative regulatory step for neuregulin-ErbB4 pathway, reduced cleavage of ErbB4 would possibly facilitate or sustain ErbB4-mediated signaling, resulting in excessive growth of cardiomyocytes, particularly in trabeculae, a phenotype seen in our TACE ⌬Zn/⌬Zn knockout mice.
Altered Mitogen Activated Protein Kinase (MAPK) pathway signaling activities in TACE ⌬Zn/⌬Zn knockout heart
The intracellular mitogen-activated protein kinase (MAPK) pathway, including ERKs, P38, and JNKs, mediates a variety of cell surface receptor signaling such as EGFR in cells. Studies have indicated that activation of p38 and ERK5, as well as their upstream MAPK kinases can induce cardiac hypertrophy (Wang et al., 1998a,b; Nemoto et al., 1998; Nicol et al., 2001) . We therefore evaluated the activation of MAPK pathways by comparing the level of their phosphorylated active form in P1 mouse heart tissues between different TACE genotypes (Fig. 6) . Interestingly, we found that the level of phosphorylated p38 (pp38) was increased, while phosphorylated ERK2 (pERK2) and JNK (pJNK) were decreased in TACE ⌬Zn/⌬Zn knockout heart compared with its wild-type littermate controls. No changes of ERK1 and ERK5 phosphorylation were observed (data not included).
Discussion
Myocardial development exhibits a unique pattern of organogenesis (Olson and Srivastava, 1996; MacLellan and Schneider, 2000) . The enlargement of the fetal heart is mainly achieved by cardiomyocyte proliferation. Whereas, shortly after birth, the cardiomyocyte permanently exits the cell cycle and loses its proliferative ability, the heart is then enlarged primarily by increasing the volume of each cardiomyocyte. This complicated process is coordinated by many factors derived from the cardiomyocytes themselves, as well as from the adjacent epicardial-derived mesenchymal cells (Manner et al., 2001) . Changes in level or activity of such homeostatic factors may contribute to developmental anomalies of the heart, and consequently abnormal cardiac "pump" function. Our data suggest that TACE is one of the factors involved in normal myocardial development.
TACE expression in fetal heart was detected at both the mRNA and protein levels. Although a relative reduction in TACE expression in total heart tissue was observed during mid-late gestation, a slight and transient increase of TACE mRNA expression was observed in E18.5 heart when most cardiomyocytes lose proliferation potential. This may suggest that TACE possibly regulate cardiomyocyte proliferation during the late fetal stage of cardiac development. Using immunohistochemistry, TACE protein was detected throughout the whole fetal heart. However, the increased TACE distribution on the endocardial side of the myocardial wall, particularly in trabeculae, may indicate an important role for TACE in trabecular formation. Null mutation of the TACE gene resulted in a severe abnormality in late gestational (E18.5) and neonatal (P1) hearts. These included enlarged total heart size and a 20ϳ30% increase in heart weight-to-body weight ratio. Morphologically, the thickness of myocardial wall, particularly the trabecular layer, was substantially increased in TACE ⌬Zn/⌬Zn knockout mouse heart. The enlargement of both left and right sides of the postnatal heart excludes the possibility that the cardiac abnormality is a compensatory response to a particular peripheral circulation problem such as reduced pulmonary circulation. Moreover, in the TACE ⌬Zn/⌬Zn knockout heart, the cardiomyocytes were enlarged, and were more loosely packed, with larger extracellular spaces, a similar pathological phenotype to that observed in "noncompaction of ventricular myocardium" (Chin et al., 1990) . The contents filling the extracellular spaces need to be further examined since no collagen accumulation was detected by trichrome staining. Unfortunately, the myocardial contractile function in TACE ⌬Zn/⌬Zn null mutants is difficult to evaluate by echocardiography since the null mutant is perinatal lethal.
While the total cardiac phenotype of the TACE ⌬Zn/⌬Zn knockout mice is unique, partial phenotypes have been observed previously in mice with other genetic deficiencies. For example, FKBP12 null mutant mice had a similar phenotype of heart enlargement accompanied by hypertrophic trabeculation. But the cardiac abnormality occured earlier (E14.5 to birth), and an additional ventricular septal defect also existed in the FKBP12 knockout mouse heart (Shou et al., 1998) . Similarly, mice with HB-EGF gene knockout had additional heart valve malformations in addition to enlarged heart by late gestation, with unchanged cardiomyocyte size (Iwamoto et al., 2003) . The cardiac hypertrophic abnormalities occurring in mice with several other genetic mutation, such as in PTEN knockout mice and in MEK5 transgenic mice, were frequently observed in adults (Crackower et al., 2002; Nicol et al., 2001) , and were associated with different molecular changes. Therefore, TACE appears to play a unique and essential role in heart development at the perinatal stage.
The possible cellular mechanisms underlying the abnormal cardiac development in TACE ⌬Zn/⌬Zn null mutant mice have been explored in our current study. Although a cardiomyocyte hypertrophy was observed in the enlarged TACE ⌬Zn/⌬Zn knockout mouse hearts, cardiac enlargement can also result from increased cardiomyocyte number (hyperplasia). Cell proliferation and cell apoptosis were then compared in P1 hearts between different TACE genotypes, and our data suggest that increased cell proliferation, but not reduced cell apoptosis, may also contribute to the abnormally enlarged heart seen in TACE ⌬Zn/⌬Zn knockout mice. Therefore, TACE might be involved in processing regulatory factors on the cell surface, which promote cells to exit from the cell cycle and control cell growth in proper size. Also, TACE may affect cell compaction through either direct effects on myocardial cells or indirect effects on mesenchymal cells.
However, the molecular mechanisms of TACE involvement in fetal heart development and modeling are still unknown. TACE, as a cell surface sheddase, is able to specifically cleave many cell surface target proteins in a variety of cell types (Killar et al., 1999) . The biological significance of such protein ectodomain shedding varies depending on the functions of the target proteins. For instance, cleavage-mediated release of cytokines and growth factors from cell surface may lead to activation and/or distal and broad-range effects. In contrast, cleavage of active receptor on cell surface may reduce its ligand binding activity and downregulate the related signaling pathway. There are several TACE-targeted proteins that may attribute to abnormal cardiac development in TACE ⌬Zn/⌬Zn null mutant mice. TGF␣ is a candidate because most of the other TACE ⌬Zn/⌬Zn knockout phenotypes, such as failure of eyelid fusion, abnormal hair and skin structure as previously reported, were also observed in TGF␣ null mutant mice (Luetteke et al., 1993) . However, there was no perinatal lethality and abnormal cardiac phenotype in TGF-␣ knockout mice. Whether abrogation of TGF␣ activity in combination with loss of other TACE-targeted protein functions results in the abnormal heart development needs further investigation. Interestingly, expression of EGFR, one of the TGF␣ receptors, and the related protein phosphorylation was dramatically reduced in the TACE ⌬Zn/⌬Zn knockout heart, indicating that EGFR signaling pathway is attenuated in the absence of functional TACE. Studies by other groups have shown that GPCR-mediated cardiac hypertrophy in adult heart usually requires HB-EGF-mediated transactivation of EGFR and other EGFR family members (ErbB2 and ErbB4) (Asakura et al., 2002; Iwamoto et al., 2003) . However, ventricular-specific ErbB2 conditional knockout mice exhibited ventricular chamber dilation, cardiomyocyte hy-pertrophy, and diminished cardiac function (Ozcelik et al., 2002; Crone et al., 2002) . ErbB2 is thought to be activated through forming heterodimers with other EGFR receptor family members, such as EGFR and ErbB4. Whether reduced EGFR activation in TACE ⌬Zn/⌬Zn knockout mice results in reduced ErbB2 activation through less heterodimer formation, and correlates with cardiomyocyte hypertrophy is unknown.
Furthermore, another member of the EGFR family, ErbB4, was found to undergo less cleavage in the P1 TACE ⌬Zn/⌬Zn knockout heart, which is consistent with previous reports that ErbB4 was subject to constitutive and regulated TACE-mediated protein cleavage in cultured cells (Rio et al., 2000) . ErbB4 and its interacting neuregulin family of EGF like ligands are already known to play essential roles in trabeculation (Gassmann et al., 1995; Meyer and Birchmeier, 1995) . Mice with neuregulin or its cognate receptor ErbB4 null mutations fail to form trabeculae and die at midgestation. In the TACE ⌬Zn/⌬Zn knockout mice, the hypertrophic trabecular phenotype and reduced cleavage of cell surface ErbB4 were observed. We speculate that TACE may work through cleavage of cell surface ErbB4, or possibly other neuregulin receptors, to regulate EGFR expression in P1 TACE ⌬Zn/⌬Zn knockout hearts was significantly reduced. In addition, reduced ErbB4 cleavage was also observed in TACE ⌬Zn/ ⌬Zn knockout heart. An anti-ErbB4 antibody that recognizes ErbB4 cytoplasmic epitopes was used for western analysis. A full length transmembrane ErbB4 was detected as a 180-kDa band, and the remaining fragment after proteolytic ectodomain shedding was detected as an 80-kDa band. The proteolytic cleavage of ErbB4 was still observed in TACE ⌬Zn/⌬Zn knockout samples, as both 180-and 80-kDa bands were detected. However, the intensity of the protease-cleaved ErbB4 protein band was significantly reduced, while the intensity of the full-length ErbB4 protein band was clearly increased in the TACE ⌬Zn/⌬Zn knockout heart compared with wild-type control, indicating less ectodomain shedding of ErbB4. GAPDH was used as a loading control. Fig. 6 . Western blot analysis of phosphorylated MAPKs in TACE ⌬Zn/⌬Zn knockout hearts. Reduced phosphorylation of ERK2 (pERK2) and JNK (pJNK), and increased phosphorylation of p38 (pp38) were detected in P1 TACE ⌬Zn/⌬Zn knockout heart samples (KO) compared with the wild-type controls (WT). Equal expression of the related MAPK protein was confirmed by Western blot using the antibodies recognizing MAPK proteins. fetal cardiac trabeculation. On the other hand, other known or unknown TACE-mediated shedding molecules may also be possibly involved in mediating the TACE ⌬Zn/⌬Zn knockout myocardial phenotype.
Downstream of the cell surface proteins, we have examined the MAPK pathway, which is a very important intracellular signal transducer connecting cell surface stimuli to nuclear effectors. Activation of MAPK in the heart can occur after GPCR agonist stimulation and other cellular stress (Clerk and Sugden, 1999; Sugden and Clerk, 1998) . MAPKs can be divided into three subfamilies: ERKs, JNKs, and p38. The role of each individual MAPK pathway in cardiac growth and hypertrophic response is not fully understood. In the TACE ⌬Zn/⌬Zn knockout heart, protein levels of MAPKs were not changed, but protein phosphorylation, which is tightly correlated to the MAPK activity, was changed. Reduced phosphorylated JNK and ERK2 were obviously detected in TACE ⌬Zn/⌬Zn knockout heart tissues, while p38 phosphorylation was clearly increased, suggesting that JNK and PRK2 pathways are downregulated, while p38-mediated pathway is activated. Whether reduced activation of JNK and ERK2 is a consequence of the reduced cell surface EGFR expression and activation seen in the TACE ⌬Zn/⌬Zn knockout heart needs to be addressed in future experiments. Similarly, the relationship between p38 activation and possibly overactivated ErbB4 due to reduced cleavage on the cell surface is another very interesting question.
In summary, the unique cardiac phenotype described herein suggests that TACE-mediated protein ectodomain shedding may be a critical regulatory process in controlling cardiomyocyte proliferation and trabeculation, effecting appropriate myocardial growth and modeling during late gestation.
